Taipei, Taiwan and Harrow, England, February 11, 2019 – An exclusive license agreement for the commercialisation of Foresee Pharmaceutical’s (6576.TWO) novel FP-001 program (leuprorelin depot), Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use subcutaneous depot formulations has been granted to Accord Healthcare.
Read MoreSandra Lee, Managing Director of Operations, explains why FMD is important and how the industry is preparing.
Read MoreThe team at Accord Fawdon recently celebrated the factory’s one-year anniversary with cakes and reflections on the successes of the past year.
Read MoreIn November 2018, at the House of Lords, Accord partnered Generics bulletin to bring influential
Read MoreWe are delighted to announce that Accord Healthcare was the most recognised company at the Global Generics & Biosimilar Awards 2018, having won awards for: Company of the Year and Biosimilar Initiative of the Year.
Read MorePelgraz - a pegylated G-CSF Biosimilar, is latest addition to Accord Healthcare's established portfolio of over 30 oncology treatments across Europe
Read MoreOver the past two weeks, we have continued to further our expansion in Europe with the opening of a new office in Basel, Switzerland and further expansion of operations in Austria.
Read MoreThe 'India Meets Britain Tracker 2018', released annually by Grant Thornton in collaboration with the Confederation of Indian Industry awards the fastest UK based companies of Indian origin.
Read More
